VEGFA and neoplasm: Moreover, clinical studies indicate that combining bevacizumab and atezolizumab overcomes ICI resistance by reversing VEGF-induced immunosuppression and enhancing CD8+ tumor-infiltrating lymphocytes (TIL) in tumors.